Found: 18
Select item for more details and to access through your institution.
Toxicological Studies of <sup>212</sup>Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial.
- Published in:
- Pharmaceuticals (14248247), 2015, v. 8, n. 3, p. 416, doi. 10.3390/ph8030416
- By:
- Publication type:
- Article
Toxicological Studies of <sup>212</sup>Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial.
- Published in:
- Pharmaceuticals (14248247), 2015, v. 8, n. 3, p. 416, doi. 10.3390/ph8030416
- By:
- Publication type:
- Article
Mutational analysis reveals Escherichia coli oriC interacts with both DnaA-ATP and DnaA-ADP during pre-RC assembly.
- Published in:
- Molecular Microbiology, 2007, v. 66, n. 2, p. 428, doi. 10.1111/j.1365-2958.2007.05930.x
- By:
- Publication type:
- Article
Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using <sup>2</sup><sup>1</sup><sup>2</sup>Pb.
- Published in:
- PLoS ONE, 2013, v. 8, n. 7, p. 1, doi. 10.1371/journal.pone.0069613
- By:
- Publication type:
- Article
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate <sup>212</sup>Pb-NNV003.
- Published in:
- PLoS ONE, 2020, v. 15, n. 3, p. 1, doi. 10.1371/journal.pone.0230526
- By:
- Publication type:
- Article
Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263230
- By:
- Publication type:
- Article
Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTRExpressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263230
- By:
- Publication type:
- Article
Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR)Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263230
- By:
- Publication type:
- Article
Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.263230
- By:
- Publication type:
- Article
Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTRExpressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263230
- By:
- Publication type:
- Article
Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTRExpressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.263230
- By:
- Publication type:
- Article
Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263230
- By:
- Publication type:
- Article
Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 1, doi. 10.2967/jnumed.121.263230
- By:
- Publication type:
- Article
Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with <sup>212</sup>Pb-TCMC-Trastuzumab.
- Published in:
- Journal of Nuclear Medicine, 2014, v. 55, n. 10, p. 1636, doi. 10.2967/jnumed.114.143842
- By:
- Publication type:
- Article
ORC formation is required for proper bacterial origin function.
- Published in:
- FASEB Journal, 2007, v. 21, n. 5, p. A658, doi. 10.1096/fasebj.21.5.a658-b
- By:
- Publication type:
- Article
DnaA-ATP-specific binding sites in E. coli oriC are required for correct timing of initiation of DNA replication.
- Published in:
- FASEB Journal, 2007, v. 21, n. 5, p. A658, doi. 10.1096/fasebj.21.5.a658-c
- By:
- Publication type:
- Article
Timing of E. coli pre-RC assembly is determined by two different growth rate-specific mechanisms.
- Published in:
- FASEB Journal, 2007, v. 21, n. 5, p. A658
- By:
- Publication type:
- Article
Preclinical study of <sup>212</sup>Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma.
- Published in:
- 2021
- By:
- Publication type:
- journal article